ULK1 as a therapeutic target in kidney diseases: Current perspective

Simple item page
dc.contributor.authorGaikwad, Anil Bhanudas
dc.date.accessioned2025-03-17T04:45:44Z
dc.date.available2025-03-17T04:45:44Z
dc.date.issued2024-11
dc.description.abstractGlobally, ~850 million people are affected by different kidney diseases. The pathogenesis of kidney diseases is intricate, where autophagy is crucial for maintaining kidney homeostasis. Iteliminates damaged organelles, thus reducing renal lesions and allowing tissue regeneration. Therefore, targeting various autophagy proteins, e.g. Unc–51–like autophagy-activating kinase 1 (ULK1), is emerging as potential therapeutic strategy against kidney disease.en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/14728222.2024.2421762
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18384
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.subjectPharmacyen_US
dc.subjectAutophagyen_US
dc.subjectKidney diseasesen_US
dc.subjectULK1en_US
dc.subjectTherapeutic targeten_US
dc.subjectKidney homeostasisen_US
dc.titleULK1 as a therapeutic target in kidney diseases: Current perspectiveen_US
dc.typeArticleen_US

Files

Collections

Department of Pharmacy